Sangamo BioSciences announced that it has completed enrollment of its Phase 2b trial of SB-509 in patients with diabetic neuropathy (DN). This double-blind, placebo-controlled trial is expected to produce efficacy data in the second half of 2011. Data generated previous studies suggests that SB-509 treatment results in statistically significant increases in nerve fiber density, nerve regeneration and an improvement in approvable end-points such as Neuropathy Impairment Score of the Lower Limb (NIS-LL) and sural nerve conduction velocity (sNCV).
SB-509 is a transcriptional activator of the gene encoding vascular endothelial growth factor-A (VEGF-A) for DN and other neurological indications including ALS.
For more information call (510) 970-6000 or visit www.sangamo.com.